...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International labmate >ATMP Development to be established at CGT Catapult
【24h】

ATMP Development to be established at CGT Catapult

机译：ATMP开发将在CGT Catapult建立

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The UK's Cell and Gene Therapy Catapult (CGT) and Rentschler Biopharma SE, a leading global contract development and manufacturing organisation (CDMO) for biopharmaceuticals, have announced that Rentschler Biopharma will establish their manufacturing capability in Advanced Therapy Medicinal Products (ATMPs), including Adeno-Associated Virus (AAV) Vectors for clinical trial supply at the CGT Catapult site in Stevenage. Under the terms of the agreement, Rentschler Biopharma will make a significant investment at the site over the next five years to set up their manufacturing capabilities, which is expected to benefit from the expertise and unique collaborative model provided by the CGT Catapult. This investment is also expected to make a major contribution to meeting the demand from UK and international researchers for suitable manufacturing capability. The development will further strengthen the UK ecosystem through the addition of Rentschler Biopharma's more than 40 years of experience and solid reputation in the development and manufacturing of biologics for both clinical and commercial supply. The company will leverage the CGT Catapult's expertise in ATMP manufacturing setup and technology development, as well as the cell and gene therapy cluster and ecosystem that has developed around Stevenage and across the UK. Dr Frank Mathias, CEO of Rentschler Biopharma said: "We are excited to take this next big step in our evolution and address the growing industry demand for ATMP manufacturing capacity and viral vector supply. With the largest industry cluster for cell and gene therapies outside the US, the UK is an ideal location for us to establish our Center of Excellence for cell and gene therapy. We look forward to working with the CGT Catapult as we invest in this growing field. They are well established in this important market, enabling us to immediately tap into the organisation's network and utilise the UK's strong expertise and supply chain in cell and gene therapy manufacturing."
机译：None

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号